FOXL2NB在结直肠癌中的表达和临床意义

doi:10.16352/j.issn.1001-6325.2023.06.0909

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 909-915.doi: 10.16352/j.issn.1001-6325.2023.06.0909

FOXL2NB在结直肠癌中的表达和临床意义

杜风¹, 陈翌阳², 张楠¹, 徐俊玄¹, 宁婷婷¹, 朱圣韬^1*, 张澍田¹

首都医科大学附属北京友谊医院 1.消化内科; 2.检验科,北京 100050

收稿日期:2023-03-03 修回日期:2023-04-19 出版日期:2023-06-05 发布日期:2023-05-31
通讯作者: ^*zhushengtao@ccmu.edu.cn
基金资助:
国家自然科学基金(82203700);中国博士后科学基金(2022M720100);博士后创新人才支持计划(BX20220216);首都医科大学附属北京友谊医院“友谊种子计划”人才项目(YYZZ202216)

Expression and clinical significance of FOXL2NB in colorectal cancer

DU Feng¹, CHEN Yiyang², ZHANG Nan¹, XU Junxuan¹, NING Tingting¹, ZHU Shengtao^1*, ZHANG Shutian¹

1. Department of Gastroenterology; 2. Department of Laboratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2023-03-03 Revised:2023-04-19 Online:2023-06-05 Published:2023-05-31
Contact: ^*zhushengtao@ccmu.edu.cn

摘要/Abstract

摘要： 目的分析叉头框L2旁基因(FOXL2NB)在结直肠癌(CRC)中的表达及临床意义,探讨FOXL2NB对CRC细胞的作用。方法 RT-qPCR和蛋白免疫印迹分析CRC组织和细胞中FOXL2NB的表达;Transwell和CCK-8实验探讨FOXL2NB在SW620细胞增殖和迁移的作用;Kaplan-Meier法和多因素Cox回归分析评估FOXL2NB对CRC预后的影响;基因集富集分析比较高、低风险组间分子信号通路差异,CIBERSORT R包计算CRC组织中FOXL2NB表达与免疫细胞浸润的关系,limma R包计算与FOXL2NB表达显著相关的分子。结果 FOXL2NB在CRC组织和细胞中的表达水平显著升高(P＜0.05);敲低FOXL2NB可抑制CRC细胞的迁移及增殖;高水平的FOXL2NB与CRC患者不良预后相关(P＜0.05),可作为CRC预后的独立风险因素(HR=2.27,95% CI=1.78~2.9,P＜0.001);FOXL2NB高表达的CRC中细胞黏附分子和肿瘤免疫相关通路被显著富集,CD8⁺ T细胞和活化树突状细胞显著增多,M0巨噬细胞显著减少。FOXL2NB基因表达与SCRT2、MGAT5B、SELENOV、FOXB1、KCNA4、LRRC14B和SLC32A1基因表达正相关。结论 FOXL2NB在CRC中高表达,可能预示CRC患者不良预后。FOXL2NB可能促进结直肠癌细胞增殖和迁移。

关键词: 结直肠癌, 叉头框转录因子, FOXL2NB, 细胞黏附, 肿瘤免疫

Abstract: Objective To analyze the forkhead box L2 neighbor (FOXL2NB) expression in colorectal cancer (CRC) and its potential clinical significance, and to explore the role of FOXL2NB in CRC cells. Methods Real time qPCR and Western blot were used to analyze the expression of FOXL2NB in CRC tissues and cells. Transwell and CCK-8 assay were used to investigate the effect of FOXL2NB on the proliferation and migration in SW620 cell line. Kaplan-Meier and multivariate Cox regression analysis were used to evaluate the prognostic significance of FOXL2NB in CRC patients. CIBERSORT R package was used to calculate the correlation between FOXL2NB expression and immune cell infiltration in CRC tissues. limma R package was used to calculate the genes that significantly correlated with FOXL2NB expression. Results The mRNA and protein levels of FOXL2NB were significantly increased in CRC cell lines and tissues (P＜ 0.05). High level of FOXL2NB was associated with shorter overall survival and progression free survival in CRC patients (P＜ 0.05), which could be used as an independent risk factor for CRC prognosis (HR=2.27, 95% CI=1.78-2.9, P＜ 0.001). FOXL2NB knockdown inhibited the migration and proliferation of CRC cells. Cell adhesion molecules and tumor immune-related pathways were significantly enriched in CRC with high FOXL2NB expression, CD8⁺ T cells and activated dendritic cells were significantly increased, while M0 macrophages were significantly decreased. FOXL2NB expression was positively correlated with SCRT2, MGAT5B, SELENOV, FOXB1, KCNA4, LRRC14B and SLC32A1 genes. Conclusions FOXL2NB is highly expressed in CRC and potentially predicts poor prognosis. FOXL2NB might promote CRC cell proliferation and migration.

Key words: colorectal cancer, forkhead box, FOXL2NB, cell adhesion, tumor immunity

中图分类号:

R735.7

杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.

DU Feng, CHEN Yiyang, ZHANG Nan, XU Junxuan, NING Tingting, ZHU Shengtao, ZHANG Shutian. Expression and clinical significance of FOXL2NB in colorectal cancer[J]. Basic & Clinical Medicine, 2023, 43(6): 909-915.

参考文献 12

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2021,71:209-249.
[2]	Ciardiello F, Ciardiello D, Martini G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine[J]. CA Cancer J Clin, 2022,72:372-401.
[3]	Gauthier L, Morel A, Anceriz N, et al. Multifunctional natural killer cell engagers targeting nkp46 trigger protective tumor immunity[J]. Cell, 2019,177:1701-1713.
[4]	Laissue P. The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis[J]. Mol Cancer, 2019,18:5.doi:10.1186/s12943-019-0938-x
[5]	Zaiss D, Coffer PJ. Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis[J]. Nat Rev Immunol, 2018,18:703-715.
[6]	Yoshida Y, Wang IC, Yoder HM, et al. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer[J]. Gastroenterology, 2007,132:1420-1431.
[7]	Du F, Qiao C, Li X, et al. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR[J]. Theranostics, 2019,9:3879-3902.
[8]	Liu J, Zhang Z, Li X, et al. Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression[J]. Oncogene, 2018,37:5477-5491.
[9]	Dai Y, Jiang Z, Qiu Y, et al. Identification of key carcinogenic genes in colon adenocarcinoma[J]. Iran J Public Health, 2022,51:364-374.
[10]	Fang Z, Huang H, Wang L, et al. Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma[J]. Front Endocrinol (Lausanne), 2022,13:968984.doi:10.3389/fendo.2022.968984
[11]	Tian S, Meng G, Zhang W. A six-mRNA prognostic model to predict survival in head and neck squamous cell carcinoma[J]. Cancer Manag Res, 2019,11:131-142.
[12]	Egen JG, Ouyang W, Wu LC. Human anti-tumor immunity: Insights from immunotherapy clinical trials[J]. Immunity, 2020,52:36-54.

[1]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[2]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[3]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[4]	张燕萍, 姚刘旭, 丁倩男, 黄则勇, 李玉红, 黄素琴. 结直肠癌PDX模型成瘤率的影响因素及临床意义[J]. 基础医学与临床, 2023, 43(4): 596-602.
[5]	邹洁, 张德德, 陶毅, 赵静, 王琼, 徐乃佳. 葛根素减轻KKAy小鼠血管内皮细胞炎性反应[J]. 基础医学与临床, 2023, 43(3): 433-437.
[6]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[7]	姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.
[8]	余宏, 丁利杰, 刘厚聪, 王纪东, 杜冀晖. 合成肽VAR2特异性结合循环肿瘤细胞的检测及临床应用[J]. 基础医学与临床, 2023, 43(11): 1662-1667.
[9]	黄薇, 凌睿云, 高乐欣, 唐文, 钱令波, 陈峰阳. 20种肿瘤化疗药物对Treg细胞增殖的影响[J]. 基础医学与临床, 2023, 43(10): 1518-1521.
[10]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[11]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[12]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[13]	张剑, 张彤, 王宏伟, 张继红, 张保祯, 董欣敏. 上调miR-433表达抑制结直肠癌细胞系增殖[J]. 基础医学与临床, 2021, 41(8): 1127-1132.
[14]	杨旭东, 于红亮, 李静, 赵春华. 巨噬细胞J774A.1外泌体促进结直肠癌细胞系MC38和CT26的增殖和迁移[J]. 基础医学与临床, 2021, 41(6): 799-804.
[15]	周堤侠, 吕海栋. 长链非编码RNA MCM3AP-AS1靶向调控miR-876-5p促进人结直肠癌细胞系的增殖和迁移[J]. 基础医学与临床, 2021, 41(2): 225-232.

FOXL2NB在结直肠癌中的表达和临床意义

Expression and clinical significance of FOXL2NB in colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价